1204246-72-9Relevant academic research and scientific papers
Synthesis of 1- and 5-(pyrazolyl)tetrazole amino and nitro derivatives
Dalinger, Igor L.,Kormanov, Alexandr V.,Vatsadze, Irina A.,Serushkina, Olga V.,Shkineva, Tatyana K.,Suponitsky, Kyrill Yu.,Pivkina, Alla N.,Sheremetev, Aleksei B.
, p. 1025 - 1034 (2016)
Regioselective introduction of nitro groups was studied in the case of pyrazoles containing a 1- or 5-tetrazole substituent at position 3(5). All the possible isomeric C-mononitropyrazoles were synthesized. The reduction of these compounds gave the respective 3(5)-amino-5(3)-tetrazolylpyrazoles, which were nitrated to 3(5)-nitramino-4-nitro-5(3)-tetrazolylpyrazoles. The reaction of 1-(nitropyrazol- 3(5)-yl)tetrazoles with hydroxylamine-O-sulfonic acid produced the respective N-amino derivatives.
4-((1H-pyrazol-3-yl)amino)phthalazin-1(2H)-one derivatives and pharmaceutical composition for use in preventing or treating cancer containing the same as an active ingredient
-
Paragraph 0211; 0218-0220, (2020/12/01)
The present invention relates to a 4-((1H-pyrazol-3-yl)amino)phthalazine-1(2H)-one derivative and a pharmaceutical composition for preventing or treating cancer containing the same as an active component. The derivative exhibits high inhibitory activity on various protein kinases, and in particular, has excellent inhibitory ability on RET proto-oncogene enzymes, and also has an excellent inhibitory effect on proliferation of medullary thyroid cancer cells and lung cancer cells expressing RET fusion genes, thereby being able to be usefully used for treating medullary thyroid cancer or lung cancer, and in particular, being able to be usefully used for treating cancer in which RET fusion genes are expressed.
ADENOSINE A3 RECEPTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF
-
, (2012/03/12)
Provided herein is a method of preventing, treating, or ameliorating one or more symptoms of an adenosine A3-mediated condition, disorder, or disease, with a compound of Formula I. Also provided herein is a method of preventing, treating, or ameliorating one or more symptoms of glaucoma or ocular hypertension. Further provided herein is a method of modulating the activity of an adenosine A3 receptor.
JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF
-
Page/Page column 166, (2010/04/03)
Provided herein are pyrrolotriazine compounds for treatment of JAK kinase, including JAK2 kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
JAK KINASE MODULATING QUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF
-
Page/Page column 95, (2010/09/17)
Provided herein are quinazoline compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions. (I).
